Login / Signup

The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.

Ashwin N AnanthakrishnanAtsushi SakurabaE L BarnesJ PekowL RaffalsM D LongR S Sandler
Published in: Alimentary pharmacology & therapeutics (2017)
The benefit of combination immunomodulator-biological therapy is stronger in those with complicated Crohn's disease, particularly early on in their disease course.
Keyphrases
  • combination therapy
  • mesenchymal stem cells
  • bone marrow